FABP1 and COVID-19: We developed a point-of-care test (POCT) using immuno-lateral flow of L-FABP and recently reported that the risk of severe disease in mild COVID-19 positive patients can be detected with 88.9% accuracy (sensitivity 100%, specificity 87.7%) by ROC analysis [10].